T1DM Immunotherapy Using Polyclonal Tregs + IL-2
NCT02772679
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
16
Enrollment
OTHER
Sponsor class
Conditions
Type 1 Diabetes Mellitus
Interventions
BIOLOGICAL:
PolyTregs+IL-2
Sponsor
Jeffrey Bluestone
Collaborators
[object Object]